Abstract: Disclosed are uracil derivatives of the formula (I): wherein R1, R2, R3, and X are as defined herein, and use thereof as therapeutic agents. The uracil derivatives are used in particular together with a cytostatic agent for suppressing or reducing resistance building up on cytostatic treatment.

Abstract: A number of thalidomide metabolites having superior anti-angiogenic properties have now been isolated and identified. In addition, thalidomide analogs that mimic the effects of the isolated and identified active thalidomide metabolites, and variations of such thalidomide analogs, have been developed. Such thalidomide analog compounds show enhanced potency in the inhibition of undesirable angiogenesis without the undesirable effects of administration of thalidomide.

Abstract: Disclosed are uracil derivatives of the formula (I): wherein R1, R2, R3, and X are as defined herein, and use thereof as therapeutic agents. The uracil derivatives are used in particular together with a cytostatic agent for suppressing or reducing resistance building up on cytostatic treatment.

Abstract: A number of thalidomide metabolites having superior anti-angiogenic properties have now been isolated and identified. In addition, thalidomide analogs that mimic the effects of the isolated and identified active thalidomide metabolites, and variations of such thalidomide analogs, have been developed. Such thalidomide analog compounds show enhanced potency in the inhibition of undesirable angiogenesis without the undesirable effects of administration of thalidomide.

Abstract: A number of thalidomide metabolites having superior anti-angiogenic properties have now been isolated and identified. In addition, thalidomide analogs that mimic the effects of the isolated and identified active thalidomide metabolites, and variations of such thalidomide analogs, have been developed. Such thalidomide analog compounds show enhanced potency in the inhibition of undesirable angiogenesis without the undesirable effects of administration of thalidomide.

Abstract: A number of thalidomide metabolites having superior anti-angiogenic properties have now been isolated and identified In addition, thalidomide analogs that mimic the effects of the isolated and identified active thalidomide metabolites, and variations of such thalidomide analogs, have been developed. Such thalidomide analog compounds show enhanced potency in the inhibition of undesirable angiogenesis without the undesirable effects of administration of thalidomide.

Abstract: Thalidomide prodrugs of the formula I: in which R is —CHR1—NHR2 or —(CH2)nCOOH; R1 is H or C1-4 alkyl; R2 is H, C1-3 alkyl, C(O)—CH2—NHR3 or an amino-protective group, R3 is H or an amino-protective group, and n is an integer from 2 to 4, in the form of their free bases or of salts with physiologically acceptable acids, as well as a process for preparation of such prodrugs and the use of such prodrugs as an active drug substance.

Abstract: The use of nitroethane derivatives of the formula I where: R1 is hydrogen, unsubstituted or substituted C1-C6-alkyl, C3-C6-alkenyl, C3-C6-alkynyl, halogen, cyano or thiocyanato; R2 is hydrogen, formyl; halogen- or C1-C3-alkoxy-substituted or unsubstituted C1-C6-alkylcarbonyl, C2-C6-alkenylcarbonyl, C4-C6-alkyldienylcarbonyl or C2-C6-alkynylcarbonyl; A is unsubstituted or substituted phenyl, naphthyl, quinolyl, quinazolyl, quinoxalyl, 1-methylindolyl, 1-methylbenzimidazolyl, 2-methylindazolyl, benzofuranyl, benzothienyl, benzoxazolyl, benzothiazolyl, furyl, thienyl, pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, oxazolyl, thiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl or triazinyl, pyranyl or thiopyranyl; as microbicides is described.

Abstract: Compounds analogous to thalidomide from the class comprising piperidine-2,6-diones are described, as are a method of preparing them and their use in drugs.

Abstract: The invention includes 5,6-dimethylpyrrolo [2,3-d]-pyrimidines (and method for their manufacture) of the formula ##STR1## or an acid-addition salt thereof, in which R is amino or hydroxy,R.sub.1 is halogen, nitro, C.sub.1 --C.sub.6 alkyl or alkoxy or CF.sub.3 and, where R is hydroxy, is also hydrogen,R.sub.2 is hydrogen, halogen or C.sub.1 --C.sub.6 -alkyl or alkoxy, andn is 1 or 2.Also included in the invention are pharmaceutical compositions containing said pyrrolo [2,3-d]-pyrimidines and the use of said compounds and compositions for treating CNS illnesses or inflammations.